The duration of fever and other symptoms after the initiation of laninamivir octanoate hydrate in the Japanese 2011-2012 influenza season.

Abstract

Laninamivir octanoate hydrate (laninamivir) is a long-acting, single inhalation neuraminidase inhibitor that was approved in Japan in 2010 for the treatment of influenza A and B virus infection. We investigated the duration of fever and other symptoms after the initiation of laninamivir in the Japanese 2011-2012 influenza season. Virus isolation was done and the 50% inhibitory concentration (IC₅₀) was measured for the virus isolates at days 1 and 5. For 211 patients (A(H3N2): 190, B: 21), the median durations of fever of A(H3N2) and B patients were 33.0 and 50.0 h, respectively (p = 0.0989). Fever was resolved within 72 h after inhalation by 89.7% of the A(H3N2) patients and by 81.0% of the patients with B. The median durations of symptoms for A(H3N2) and B patients were 89.0 and 94.0 h, respectively (p = 0.5809). On day 5, the influenza virus-positive rates for A(H3N2) and B patients were significantly different: 25.8% (40/155) and 70.6% (12/17), respectively (p < 0.0001). No significant change in IC₅₀ value was found between day 1 and day 5 for any of the four tested neuraminidase inhibitors, and no IC₅₀ value exceeded 50 nM. The incidence of adverse drug reactions was 1.3% (3/234), with no serious reactions reported. These results show that laninamivir was effective for the treatment of both influenza A(H3N2) and B in this study, with no safety issues. The clinical effectiveness of laninamivir for A(H3N2) was superior to that for B.

• Authors: Hideyuki Ikematsu, Naoki Kawai, Norio Iwaki, Seizaburo Kashiwagi
• Journal: Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy (J Infect Chemother) Vol. 20 Issue 2 Pg. 81-5 (Feb 2014) ISSN: 1437-7780 [Electronic] Netherlands
• PMID: 24486167 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2013. Published by Elsevier Ltd.

Chemical References

• Antiviral Agents
• Guanidines
• Pyrans
• Sialic Acids
• laninamivir
• Zanamivir

Topics

• Adolescent
• Adult
• Aged
• Aged, 80 and over
• Antiviral Agents (adverse effects, therapeutic use)
• Child
• Child, Preschool
• Female
• Fever (virology)
• Guanidines
• Humans
• Influenza A Virus, H3N2 Subtype (drug effects, isolation & purification)
• Influenza B virus (drug effects, isolation & purification)
• Influenza, Human (drug therapy, physiopathology, virology)
• Inhibitory Concentration 50
• Male
• Middle Aged
• Pyrans
• Sialic Acids
• Young Adult
• Zanamivir (adverse effects, analogs & derivatives, therapeutic use)